Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091286 · ClinicalTrials.gov registry record · Early Phase 1
Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer
A Early Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT00091286 is a Early Phase 1 study that was terminated before completion, run by Craig L Slingluff, Jr. The registered enrollment target is 11 participants.
The verdict
NCT00091286, a Early Phase 1 study, was terminated before completion, sponsored by Craig L Slingluff, Jr.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with stage IIB, stage III, or stage IV colorectal cancer.
Interventions
- BIOLOGICAL HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2003-03-24 |
| Est. Completion | 2008-02-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091286
The ClinicalTrials.gov registry entry for NCT00091286 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine is the first listed.
NCT00091286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091286 about?
NCT00091286 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer". RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with stage IIB, stage III, or stage IV colorectal cancer.
What is the current status of trial NCT00091286?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2003-03-24. Estimated completion is 2008-02-15.
What interventions are being tested in trial NCT00091286?
The interventions under investigation include: HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00091286?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.